

Online Supplemental Table A. Sites of metastatic disease.

Sites of metastatic disease	STn-KLH N = 521 N (%)	Control N = 501 N (%)	Total N = 1022 N (%)
Bone	333 (63.9%)	294 (58.7%)	627 (61.3%)
Liver	211 (40.5%)	221 (44.1%)	432 (42.3%)
Lung	170 (32.6%)	175 (33.6%)	345 (33.7%)
Lymph node	139 (26.7%)	158 (30.3%)	297 (29.1%)
Pleural effusion	77 (14.8%)	84 (16.1%)	161 (15.7%)
Other	42 (8.1%)	40 (7.7%)	82 (8.0%)
Mediastinum	42 (8.1%)	46 (9.2%)	88 (8.6%)
Soft tissue (not breast)	45 (8.6%)	28 (5.4%)	73 (7.1%)
Chest wall	36 (6.9%)	35 (6.7%)	71 (6.9%)
Pleura	36 (6.9%)	30 (5.7%)	66 (6.4%)
Skin	36 (6.9%)	28 (5.4%)	64 (6.3%)
Right breast	14 (2.7%)	15 (3.02.9%)	29 (2.8%)
Ascites	17 (3.3%)	11 (2.21%)	28 (2.7%)
Left breast	12 (2.3%)	14 (2.7%)	26 (2.5%)
CNS	1 (0.2%)	7 (1.3%)	8 (0.8%)
Kidney	1 (0.2%)	2 (0.4%)	3 (0.3%)
Unknown	0	0	0

Some overlap of metastatic sites exists, as most patients had multiple sites of metastasis.

Note: There are no significant differences between treatment and control arms at an unadjusted $\alpha = 0.05$.

Online Supplemental Table B. Patient dropouts due to adverse events.

Associated adverse event	Day of discontinuation* (number of vaccinations)
Myelodysplastic syndrome not otherwise specified (NOS)	562 (13)
Congestive cardiac failure	28 (1)
Dry gangrene	32 (2)
Thrombocytopenic purpura	119 (5)
Lung infiltration NOS	510 (11)
Angioneurotic edema	15 (1)
Injection site ulcer	111 (4)
Injection site reaction	117 (5)
Hypotension NOS	15 (1)
Injection site ulceration	89 (4)
Renal failure acute	160 (7)
Atrial fibrillation	1337 (21)

*Relative to baseline data

Online Supplemental Table C. Ulceration characterization.

Treatment group	Number of patients dosed	Incidence <i>N</i> (%)	Mild <i>N</i> (%)	Moderate <i>N</i> (%)	Severe <i>N</i> (%)
STn-KLH	520	91 (17.5)	24 (4.6)	52 (10.0)	15 (2.9)
KLH	500	88 (17.6)	27 (5.4)	45 (9.0)	16 (3.2)

Online Supplemental Table D. Safety data: Top 10 adverse events (all grades) by frequency.

Adverse event	STn-KLH	KLH
Nausea	23.5%	24.6%
Injection site ulcerations	17.5%	17.6%
Arthralgia	16.6%	16.4%
Fatigue	15.5%	17.2%
Headache	13.8%	17.2%
Back pain	13.4%	15.0%
Vomiting	11.5%	13.9%
Pyrexia	11.5%	12.3%
Cough	10.7%	10.1%
Bone pain	9.8%	11.1%

Online Supplemental Table E. Number of patients with various antibody titers at week 12.

	STn-KLH N=364			KLH N=323		
	Less than median (<i>n</i>)	Equal to median (<i>n</i>)	Greater than median (<i>n</i>)	Less than median (<i>n</i>)	Equal to median (<i>n</i>)	Greater than median (<i>n</i>)
OSM						
IgM	145	102	120	0	128	48
IgG	125	69	173	0	303	23
STn						
IgM	183	83	101	0	181	145
IgG	157	104	106	0	295	31
KLH						
IgM	106	82	179	129	66	131
Igg	159	99	109	122	73	131